TGFB1 and systemic sclerosis: Indeed, aberrant TGF-β signaling has been recognized in a wide spectrum of fibrotic diseases, not limited to systemic sclerosis [107], keloid [108], pulmonary fibrosis [109], hepatic fibrosis [110], renal fibrosis [111], cardiac fibrosis [112], myopathies [113], and salivary gland fibrosis [114].